IgA1 Protease Treatment Reverses Mesangial Deposits and Hematuria in a Model of IgA Nephropathy.

about

Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?Biomarkers and targeted new therapies for IgA nephropathy.IgA nephropathy enigma.Case report on pathogenetic link between gluten and IgA nephropathy.

P2860

Q38860793-1C2FB7BD-C382-492F-8763-D07F564B340D Q38871090-E2C0F9EA-F140-4560-A661-CEE6D0F89442 Q38904812-AECA9D8C-EFF9-424C-95AF-619B8462A56C Q54963030-148CEB50-ED04-4F6D-B232-561CCB755FC2

P2860

IgA1 Protease Treatment Reverses Mesangial Deposits and Hematuria in a Model of IgA Nephropathy.

Item

http://www.wikidata.org/entity/Q40974297

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

IgA1 Protease Treatment Revers ...... in a Model of IgA Nephropathy.

@en

type

Item

label

IgA1 Protease Treatment Revers ...... in a Model of IgA Nephropathy.

@en

prefLabel

IgA1 Protease Treatment Revers ...... in a Model of IgA Nephropathy.

@en

P1476

IgA1 Protease Treatment Revers ...... in a Model of IgA Nephropathy

@en

P2093

Aiqun Li

http://www.w3.org/2001/XMLSchema#string

Christelle Moal

http://www.w3.org/2001/XMLSchema#string

Christina Papista

http://www.w3.org/2001/XMLSchema#string

Erwan Boedec

http://www.w3.org/2001/XMLSchema#string

Julie Bex-Coudrat

http://www.w3.org/2001/XMLSchema#string

Julien Maillard

http://www.w3.org/2001/XMLSchema#string

Lilia Abbad

http://www.w3.org/2001/XMLSchema#string

Marie-Bénédicte Le Stang

http://www.w3.org/2001/XMLSchema#string

Paolo G V Martini

http://www.w3.org/2001/XMLSchema#string

Sebastian M Lechner

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a human immunodominant B-cell epitope within the immunoglobulin A1 protease of Streptococcus pneumoniae.

Premature replacement of mu with alpha immunoglobulin chains impairs lymphopoiesis and mucosal homing but promotes plasma cell maturation.

A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy.

The IgA1 proteases of pathogenic bacteria.

Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments

A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group.

Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy

Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity

Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy

Transglutaminase is essential for IgA nephropathy development acting through IgA receptors.

P304

2622-2629

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2015080856

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Renato Monteiro

Laureline Berthelot

Agnès Jamin

P577

2016-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26850635

http://www.w3.org/2001/XMLSchema#string

P932

5004657

http://www.w3.org/2001/XMLSchema#string

IgA1 Protease Treatment Reverses Mesangial Deposits and Hematuria in a Model of IgA Nephropathy.

about

P2860

P2860

IgA1 Protease Treatment Reverses Mesangial Deposits and Hematuria in a Model of IgA Nephropathy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932